StockData
LeMaitre Vascular Inc logo

LeMaitre Vascular Inc (LMAT) stock

LMATNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 22/3022% below fair value
$75.58−0.52 (-0.68%)

Close on Nov 18, 2026Market cap $1.73BP/E 26.5Yield 1.06%

Earnings

LeMaitre Vascular's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$68.00M
+11.5% on a year earlier
Adjusted earnings per share, Q3 FY2026
$0.65
$0.62 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 10 items

Quarterly results

Revenue and earnings per share from each of LeMaitre Vascular's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$68.00M+11.5%$0.65$0.65Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026after the close$70.40M+9.7%$0.74–Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$66.60M+11.2%$0.68–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$64.50M+15.8%$0.68–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$61.00M+11.3%$0.75$0.62Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$64.20M+15.1%$0.60–Release
Q1 FY2025ended Mar 31, 2025May 1, 2025after the close$59.87M+11.9%$0.48–Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$55.70M+13.9%$0.49$0.49Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024after the close$54.80M+15.6%$0.49–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$55.80M+11.4%$0.52–Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close$53.50M+13.6%$0.44–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

LeMaitre Vascular's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
SalesGAAPQ4 FY2026$69.90M – $71.90M–NewNov 4, 2026
SalesQ4 FY2026$71.10M – $73.10M–NewAug 4, 2026
Gross MarginGAAPQ4 FY202672.1%–NewNov 4, 2026
Op. IncomeGAAPQ4 FY2026$18.80M – $20.20M–NewNov 4, 2026
Op. IncomeQ4 FY2026$19.80M – $21.20M–NewAug 4, 2026
Op. Margin (Mid)GAAPQ4 FY202627%–NewNov 4, 2026
EPSGAAPQ4 FY2026$0.70 – $0.75–NewNov 4, 2026
EPSQ4 FY2026$0.75 – $0.81–NewAug 4, 2026
SalesGAAPFY2026$274.80M – $276.80M–NewNov 4, 2026
SalesFY2026$274.30M – $278.30M$277.00M – $283.00MLoweredAug 4, 2026
Gross MarginGAAPFY202672.1%–NewNov 4, 2026
Op. IncomeGAAPFY2026$74.60M – $76.10M–NewNov 4, 2026
Op. IncomeFY2026$75.30M – $78.20M$77.60M – $82.00MLoweredAug 4, 2026
Op. Margin (Mid)GAAPFY202627%–NewNov 4, 2026
EPSGAAPFY2026$2.77 – $2.82–NewNov 4, 2026
EPSFY2026$2.84 – $2.94$2.93 – $3.08LoweredAug 4, 2026

Guidance vs results

The last range LeMaitre Vascular gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026EPS (GAAP)$0.66 – $0.71$0.65Below range
Q3 FY2026Revenue$66.30M – $68.30M$68.00MWithin range
Q2 FY2026EPS (GAAP)$0.79 – $0.84$0.74Below range
Q2 FY2026Revenue$70.50M – $72.50M$70.40MBelow range
Q1 FY2026EPS (GAAP)$0.64 – $0.69$0.68Within range
Q1 FY2026Revenue$65.60M – $67.60M$66.60MWithin range
FY2025EPS (GAAP)$2.48 – $2.53$2.51Σ4QWithin range
FY2025Revenue$247.00M – $249.00M$249.57MΣ4QAbove range
Q4 FY2025EPS (GAAP)$0.64 – $0.69$0.68Within range
Q4 FY2025Revenue$61.80M – $63.80M$64.50MAbove range
Q3 FY2025EPS (GAAP)$0.54 – $0.59$0.75Above range
Q3 FY2025Revenue$61.20M – $63.20M$61.00MBelow range

Guidance history

Every forecast LeMaitre Vascular put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026EPSFY2026$2.77 – $2.82New
Nov 4, 2026EPSQ4 FY2026$0.70 – $0.75New
Nov 4, 2026Gross MarginQ4 FY202672.1%New
Nov 4, 2026Gross MarginFY202672.1%New
Nov 4, 2026Op. IncomeQ4 FY2026$18.80M – $20.20MNew
Nov 4, 2026Op. IncomeFY2026$74.60M – $76.10MNew
Nov 4, 2026Op. Margin (Mid)Q4 FY202627%New
Nov 4, 2026Op. Margin (Mid)FY202627%New
Nov 4, 2026SalesQ4 FY2026$69.90M – $71.90MNew
Nov 4, 2026SalesFY2026$274.80M – $276.80MNew
Aug 4, 2026EPSFY2026$2.84 – $2.94Lowered
Aug 4, 2026EPSQ3 FY2026$0.66 – $0.71New
Aug 4, 2026EPSQ4 FY2026$0.75 – $0.81New
Aug 4, 2026Op. IncomeFY2026$75.30M – $78.20MLowered
Aug 4, 2026Op. IncomeQ3 FY2026$17.30M – $18.80MNew
Aug 4, 2026Op. IncomeQ4 FY2026$19.80M – $21.20MNew
Aug 4, 2026SalesFY2026$274.30M – $278.30MLowered
Aug 4, 2026SalesQ3 FY2026$66.30M – $68.30MNew
Aug 4, 2026SalesQ4 FY2026$71.10M – $73.10MNew
May 5, 2026EPSQ2 FY2026$0.79 – $0.84New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases LeMaitre Vascular filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?